Abstract: A method for in vivo electrotherapy, or electroporation-mediated therapy, using a needle array apparatus is provided. Treatment of tumors with a combination of electroporation using the apparatus of the invention, and a chemotherapeutic agent, caused regression of tumors in vivo.
Type:
Grant
Filed:
October 25, 1999
Date of Patent:
September 17, 2002
Assignee:
Genetronics, Inc.
Inventors:
Sukhendo B. Dev, Gunter A. Hofmann, Richard A. Gilbert, Yasuhiko Hayakawa, Richard Heller, Mark J. Jaroszeski
Abstract: The present invention features biarsenical molecules. Target sequences that specifically react with the biarsenical molecules are also included. The present invention also features kits that include biarsenical molecules and target sequences. Tetraarsenical molecules are also featured in the invention.
Type:
Grant
Filed:
August 11, 1999
Date of Patent:
September 17, 2002
Assignee:
The Regents of the University of California
Abstract: Duplex polynucleotides containing damage or errors are detected with hindered intercalating compounds which are capable of intercalating only in the presence of such damage or error. Conditions characterized by the presence of polynucleotide errors or damage are treated with such compounds that are capable of catalyzing polynucleotide cleavage with light.
Type:
Grant
Filed:
November 23, 1999
Date of Patent:
September 3, 2002
Assignee:
California Institute of Technology
Inventors:
Jacqueline K. Barton, Brian A. Jackson, Brian P. Hudson
Abstract: Disclosed is a process for forming a normalized genomic DNA library from an environmental sample by (a) isolating a genomic DNA population from the environmental sample; (b) at least one of (i) amplifying the copy number of the DNA population so isolated and (ii) recovering a fraction of the isolated genomic DNA having a desired characteristic; and (c) normalizing the representation of various DNAs within the genomic DNA population so as to form a normalized library of genomic DNA from the environmental sample. Also disclosed is a normalized genomic DNA library formed from an environmental sample by the process.
Abstract: This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent disorders with CD14 mediated cell activation, such as sepsis.
Type:
Grant
Filed:
October 13, 1998
Date of Patent:
September 3, 2002
Assignee:
The Scripps Research Institute
Inventors:
Didier J. Leturcq, Ann M. Moriarty, Richard J. Ulevitch, Peter S. Tobias, John C. Mathison
Abstract: Disclosed is a process of performing Sexual PCR which includes generating random polynucleotides by interrupting or blocking synthesis or amplification process to slow or halt synthesis or amplification of at least one polynucleotides, optionally amplifying the polynucleotides, and reannealing the polynucleotides to produce random mutant polynucleotides. Also provided are vector and expression vehicles including such mutant polynucleotides, polypeptides expressed by the mutant polynucleotides and a method for producing random polypeptides.
Abstract: A novel neuronal cell growth factor, neuronal-activity regulated pentraxin, Narp, is provided, as well as polynucleotides encoding Narp. Narp is useful for induction of dendritic neurite outgrowth as well as promotion of neuronal migration. Methods for treatment of subjects having a neuronal cell disorder, utilizing Narp of the invention, are also provided.
Type:
Grant
Filed:
June 16, 1998
Date of Patent:
August 20, 2002
Assignee:
The Johns Hopkins University School of Medicine
Abstract: Growth differentiation factor Lefty-1 polypeptide and polynucleotides are provided herein. Also disclosed are diagnostic and therapeutic methods of using the Lefty-1 polypeptide and polynucleotide sequences.
Type:
Grant
Filed:
January 31, 2000
Date of Patent:
August 6, 2002
Assignee:
The Johns Hopkins University School of Medicine
Abstract: A purified thermostable enzyme is derived from the archael bacterium Thermococcus GU5L5. The enzyme has a molecular weight of about 68.5 kilodaltons and has cellulase activity. The enzyme can be produced from native or recombinant host cells and can be used for the removal of arginine, phenylalanine, or methionine amino acids from the N-terminal end of peptides in peptide or peptidomimetic synthesis. The enzyme is selective for the L, or ‘natural’ enantiomer of the amino acid derivatives and is therefore useful for the production of optically active compounds. These reactions can be performed in the presence of the chemically more reactive ester functionally, a step which is very difficult to achieve with nonenzymatic methods.
Type:
Grant
Filed:
June 30, 2000
Date of Patent:
August 6, 2002
Assignee:
Diversa Corporation
Inventors:
Dennis Murphy, John Reid, Dan Robertson
Abstract: The present invention relates to multi-well platforms, lids, caddies and any combination thereof The multi-well platforms comprise a plurality of wells that can be of any shape and can be arranged in any ornamental pattern. The lid comprises an area corresponding to the well field. The caddy has a footprint approximately that of a standard 96-well microtiter plate. When the multi-well platform is engaged with the caddy, the wells of the well-field of the multi-well platform are preferably not obscured by the caddy when viewed from the bottom of the combination.
Type:
Grant
Filed:
July 7, 1998
Date of Patent:
July 30, 2002
Assignee:
Aurora Biosciences Corporation
Inventors:
Andrew A. Pham, Peter J. Coassin, Alec Tate Harootunian, Peter N. Pham, Chari Stylli, Roger Y. Tsien
Abstract: Growth differentiation factor-15 (GDF-15) polynucleotide sequence and amino acid sequence are provided herein. Also described are diagnostic and therapeutic methods of using GDF-15 polypeptide and polynucleotide sequences.
Type:
Grant
Filed:
March 30, 2000
Date of Patent:
July 16, 2002
Assignee:
The Johns Hopkins University School of Medicine
Inventors:
Se-Jin Lee, Thanh Huynh, Suzanne Sebald, Christopher Rankin, Edward Hsiao
Abstract: A method for in vivo electrotherapy, or electroporation-mediated therapy, using a needle array apparatus is provided. Treatment of tumors with a combination of electroporation using the apparatus of the invention, and a chemotherapeutic agent, caused regression of tumors in vivo.
Type:
Grant
Filed:
April 18, 2000
Date of Patent:
July 9, 2002
Assignee:
Genetronics, Inc.
Inventors:
Gunter A. Hofmann, Richard A. Gilbert, Richard Heller, Mark J. Jaroszeski
Abstract: This invention relates to chemical compositions useful in protecting amino functional groups, e.g., during synthetic organic chemistry procedures or in the formulation and/or delivery of prodrugs. The present invention relates particularly to amino-protecting species comprising an acyl group that can form an amide bond with an amino group. The protecting groups of the present invention can be conveniently removed under a wide variety of conditions.
Type:
Grant
Filed:
June 30, 2000
Date of Patent:
July 9, 2002
Assignee:
The Regents of the University of California, San Diego
Inventors:
Murray Goodman, Christopher J. Creighton
Abstract: This invention relates to oligonucleotides complementary to the IGF-II genes which modulate tumor cell growth in mammals. This invention is also related to methods of using such compounds in inhibiting the growth of tumor cells in mammals. This invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable excipient and an effective amount of a compound of this invention.
Type:
Grant
Filed:
April 22, 1999
Date of Patent:
July 9, 2002
Assignee:
Genesense Technologies Inc.
Inventors:
Jim A. Wright, Aiping H. Young, Yoon S. Lee
Abstract: The present invention is based on the discovery of a simplified assay for identifying modulators of ubiquitin ligase activity. This assay allows detection of compounds that affect ubiquitination and thus, cell cycle regulation in cells. An increase in ubiquitination, in comparison to a test sample lacking a test compound, indicates a stimulation of activity, whereas a reduction in ubiquitination indicates an inhibitor of activity. Also disclosed herein are methods of identifying proteins having ubiquitin ligase activity, methods of identifying substrates for ubiquitination, methods for identifying an activity relationship between a particular ubiquitin ligase and a particular ubiquitin conjugating enzyme, and chimeric proteins comprising a ubiquitin conjugating enzyme and a ubiquitination substrate, which are useful in all of the disclosed methods.
Type:
Grant
Filed:
August 6, 1999
Date of Patent:
July 2, 2002
Assignee:
California Institute of Technology
Inventors:
Raymond J. Deshaies, R. M. Renny Feldman
Abstract: Catalase enzymes derived from bacteria from the genera Alcaligenes (Deleya) and Microscilla are disclosed. The enzymes are produced from native or recombinant host cells and can be utilized to destroy or detect hydrogen peroxide, e.g., in production of glyoxylic acid and in glucose sensors, and in processes where hydrogen peroxide is used as a bleaching or antibacterial agent, e.g. in contact lens cleaning, in bleaching steps in pulp and paper preparation and in the pasteurization of dairy products.
Type:
Grant
Filed:
October 5, 1999
Date of Patent:
June 25, 2002
Assignee:
Diversa Corporation
Inventors:
Dan E. Robertson, Indrajit Sanyal, Robert S. Adhikary
Abstract: This invention provides an optical probe useful as an optical probe or sensor of post translational type modifications, such as phosphorylation. The invention comprises a polypeptide moiety, which contains a recognition motif for a post translational type activity and a protease site, which is coupled to a probe moiety. Modification of the polypeptide, by the post translational type activity, results in a modulation of the rate at which a protease cleaves the polypeptide which is sensed by a measurable change in at least one optical property of the optical probe upon cleavage. The present invention also includes a recombinant nucleic acid molecule that encodes an optical probe and a vector and host cell or library of cells that include the recombinant nucleic acid molecule. The optical probe can be used in methods to determine whether a sample, including a cell or a sample from an organism, contains a post-translational type modification activity.
Type:
Grant
Filed:
May 5, 1999
Date of Patent:
June 25, 2002
Assignee:
Aurora Biosciences Corporation
Inventors:
Brian A. Pollok, Brian D. Hamman, Steven M. Rodems, Lewis R. Makings
Abstract: Growth differentiation factor-3 (GDF-3) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-3 polypeptide and polynucleotide sequences.
Type:
Grant
Filed:
September 3, 1999
Date of Patent:
May 21, 2002
Assignee:
The Johns Hopkins University School of Medicine
Abstract: Y—X—C(R′)═C(R″)COOR′″ (A1)
The present invention relates to novel protein tyrosine phosphatase modulating compounds having the general structure shown in Formula (A1), to methods for their preparation, to compositions comprising the compounds, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation of the activity of molecules with phosphotyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in in vitro systems, microorganisms, eukaryoic cells, whole animals and human beings. R′ and R″ are independently selected from the group consisting of hydrogen, halo, cyano, nitro, trihalomethyl, alkyl, arylalkyl.